Pertussis toxin they are formed from two subunits. The "A" subunit possesses enzyme activity, and is transferred to the host cell following a conformational change in the membrane-bound transport "B" subunit. Pertussis toxin is an exotoxin with six subunits (named "S1" through "S5"—each complex contains two copies of "S4"). The subunits are arranged in "A-B" structure: the "A" component is enzymatically active and is formed from the S1 subunit, while the "B" component is the receptor-binding portion and is made up of subunits S2–S5. The subunits are encoded by "ptx" genes encoded on a large PT operon that also includes additional genes
Schindler disease of the disease is mostly palliative. However, Type II Schindler disease, with its late onset of symptoms, is not characterized by neurological degeneration. There is no known cure for Schindler disease, but bone marrow transplants have been trialed, as they have been successful in curing other glycoprotein disorders. Schindler disease was named after Detlev Schindler (1946- ) M.D., the first author of a 1988 paper detailing the disease. It also named after the Japanese Biochemist and Physician, Hiro Kanzaki (1949- ), who further studied it and released papers detailing the disease in 2006. Schindler disease Schindler disease, also known as